Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.47 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 2/20 | 0.34 |
| ▸ | LCAT | P04180 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10141642 | 0.88 | ACACB (0.41) | ACACBGPR119LCAT | |
| SCHEMBL10141634 | 0.86 | ACACB (0.40) | ACACBGPR119 | |
| SCHEMBL10141633 | 0.85 | HRH3 (0.42) | ACACBPANK3GPR119OGALCAT | |
| SCHEMBL11402871 | 0.82 | ACACB (0.50) | ACACBPANK3OGALCAT | |
| SCHEMBL10150967 | 0.82 | ACACB (0.46) | ACACBPANK3GPR119OGALCAT | |
| SCHEMBL10121068 | 0.81 | ACACB (0.49) | ACACBPANK3OGALCATSMO | |
| SCHEMBL29929322 | 0.81 | ACACB (0.52) | ACACBPANK3OGALCAT | |
| SCHEMBL13187881 | 0.81 | ACACB (0.49) | ACACBPANK3OGALCATSMO | |
| SCHEMBL13466381 | 0.81 | ACACB (0.52) | ACACBPANK3OGALCAT | |
| SCHEMBL10141643 | 0.80 | ACACB (0.41) | ACACBPANK3GPR119LCAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ACACB 265/4885PANK3 1433/4885GPR119 1577/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | ACACB 213/4885PANK3 1499/4885GPR119 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.